Proteros Biostructures ( and Boehringer Ingelheim Pharmaceuticals ( are collaborating in the field of protein crystallography. The partnership will run for 18 months, and Proteros will receive research funding fees and success payments for the generation and analyses of protein-ligand-structures of hits and evolved chemical entities from in-house Boehringer Ingelheim programs.

“Proteros will apply its proprietary Free Mounting System (FMS™) and Picodropper™ technologies to maximize data quality and success rates, thus allowing rapid evolution of multiple hit series at Boehringer Ingelheim,” says Torsten Neuefeind, Ph.D., CEO of Proteros.

Next articleUMMZ Periodical Cicada Page